ZBD(SH:603567) Zhong Guo Jing Ji Wang·2025-11-10 05:41Core Viewpoint - The company is enhancing its competitive edge in the traditional Chinese medicine (TCM) sector through strategic collaborations, supply chain integration, and advanced manufacturing technologies, aiming for a comprehensive and efficient industry chain from cultivation to market [1][5]. Group 1: Strategic Collaborations - The company has partnered with Longjiang Forest Industry Group to establish a GAP planting base for Siberian ginseng, focusing on eight key areas including TCM supply and shared medical channels [1]. - This collaboration signifies a new phase of large-scale replication of the company's full industry chain synergy model, reflecting deep integration of "industry chain + manufacturing chain + innovation chain" [1]. Group 2: Market Positioning and Resource Integration - The company has developed the "Shennongzhou Traditional Chinese Medicine Health Theme Street" and an efficient spot trading area at its Bozhou TCM trading center, attracting over 2,000 pharmaceutical companies [2]. - The strategic layout extends to Southwest China, with a partnership between its subsidiary Guizhou Shennong Valley and the Guizhou TCM Industry Association to build a modern collaborative supply chain [2]. - This initiative enhances the company's control over key TCM resource areas and provides stable, high-quality raw material support for its industrial segment [2]. Group 3: Manufacturing and Quality Assurance - The company has established a mature smart factory system, achieving industry-leading stability in drug batch quality through a smart quality control platform [3]. - The transition from "experience manufacturing" to "scientific manufacturing" has been facilitated by the construction of national-level green factories and collaboration with Zhejiang University on a TCM CMC smart factory [3]. - The company plans to fully implement its "AI + medicine" strategy by 2025, utilizing AI technologies to ensure high product quality and consistency [3]. Group 4: Marketing Strategies - The company employs a differentiated market development strategy, rapidly covering various medical terminals through a dual-track approach of "medical institution penetration + grassroots network building" [4]. - Key cardiovascular products have shown stable growth in tiered hospitals and significant expansion in county markets, driven by collective procurement policies [4]. - The increasing number of terminal developments and quality customer contracts is expected to lead to a new phase of explosive growth in marketing performance [4]. Group 5: Performance Growth Drivers - The company has achieved efficient collaboration and value multiplication across its entire industry chain through resource integration, smart manufacturing upgrades, and innovative marketing strategies [5]. - Deep cooperation with strategic partners like Longjiang Forest Industry Group has further connected the industry loop from cultivation to terminal sales [5]. - Upcoming milestones, including clinical advancements and the release of new chemical drug varieties, are anticipated to provide robust growth momentum for the company's future performance [5].